SePkLin Study: Pragmatic, Multicenter, Randomized, Controlled Clinical Trial in Patients with Sepsis to Evaluate the Safety and Efficacy of Personalized Pk/Pd Dosing Versus Standard Dosing of LINezolid.
This research study, called the SePkLin Study, is for people who have sepsis, which is a life-threatening reaction to an infection. It's investigating the antibiotic linezolid, a common medicine used to fight severe infections. The main goal is to compare two ways of giving linezolid: the usual standard dose, versus a personalised dose that is adjusted for each patient. Researchers want to see if a personalised dose can be safer and more effective, particularly in preventing a side effect called thrombocytopenia, where blood platelet levels drop too low. They will also look at other important things like how well patients recover, if the infection comes back, and how long people stay in intensive care.
At a glance
What is this study about?
Sepsis is a very serious condition caused by your body's extreme response to an infection. It can be life-threatening and needs urgent medical attention. Antibiotics are crucial for treating sepsis, but sometimes they can have side effects. This study is focusing on an antibiotic called linezolid.
Linezolid is a powerful medicine often used for severe infections. The researchers want to find the best way to give this antibiotic to people with sepsis. They are comparing giving everyone the same standard dose with giving a personalised dose that is specifically tailored to each patient. The idea behind personalised dosing is that different people react to medicines in different ways, so adjusting the amount given might lead to better results and fewer side effects.
The main thing the study is looking for is how often patients develop a condition called thrombocytopenia. This is when the number of tiny cells in your blood called platelets drops too low. Platelets are important for stopping bleeding, so having too few can be a problem. The study wants to see if giving a personalised dose of linezolid can help reduce the chance of this happening. They will also be looking at other important aspects like how quickly people recover, if the infection returns, and how long they need to stay in hospital, particularly in critical care.
Key takeaways
- The study is for adults with sepsis.
- It compares standard versus personalised dosing of an antibiotic called linezolid.
- The main aim is to see if personalised dosing reduces low platelet counts (thrombocytopenia).
- Overall health, recovery, and hospital stay duration are also being monitored.
- Participation involves close monitoring for about 28 days.
Who may be eligible?
This study is open to adults aged 18 and over, with no upper age limit. Both men and women can take part. To be considered for this study, you must have been diagnosed with sepsis, as this is the specific condition the researchers are investigating.
There may be other specific health requirements or conditions that would mean you can't join the study, even if you have sepsis and are over 18. These often relate to other medical conditions you might have, or other medications you are taking, which could affect how the study medicine works or make it unsafe for you.
Your doctor will review your full medical history and current health status very carefully to determine if this study is suitable for you. They will explain all the criteria in detail and answer any questions you have about whether you meet the requirements to participate.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with sepsis?
- Are you able to provide consent (or can a legal representative provide it for you)?
- Are you comfortable with regular blood tests and monitoring?
What does participation involve?
If you decide to take part in this study, you would be randomly assigned to receive linezolid either at a standard dose or a personalised dose. This means a computer decides which group you are in, like flipping a coin. You will receive the antibiotic as part of your sepsis treatment.
Researchers will regularly take blood samples to check your platelet count and possibly levels of the antibiotic in your body. They will also closely monitor your overall health, how your sepsis is progressing, and any symptoms you might have. This monitoring will happen during your hospital stay and for a period after, specifically up to 28 days after starting treatment. The total duration of your participation, including follow-up, will be around 28 days.
Potential risks and benefits
Locations (1)
- —UnverifiedSpain
Common questions
What is sepsis?
Sepsis is a very serious, life-threatening reaction your body has to an infection. It needs urgent medical treatment.
What is linezolid?
Linezolid is an antibiotic used to treat severe bacterial infections, often given when other antibiotics might not be effective.
What does 'personalised dosing' mean?
It means the amount of medicine you receive is adjusted specifically for you, based on factors like your weight, kidney function, or how your body handles the drug.
What is thrombocytopenia?
Thrombocytopenia means having a low number of platelets in your blood. Platelets are important for helping your blood clot and stopping bleeding.
Will I know if I'm getting a standard or personalised dose?
No, you won't know which group you are in. This is called 'blinding' and helps ensure the study results are fair and unbiased.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.